| 1. |
Guyatt G, Baumann M, Pauker S, et al. Addressing resource allocation issues in recommendations from clinical practice guideline panels: suggestions from an American College of Chest Physicians task force. Chest, 2006, 129(1): 182-187.
|
| 2. |
Eddy DM. Comparing benefits and harms: the balance sheet. JAMA, 1990, 263(18): 2493, 2498, 2501.
|
| 3. |
Magpie Trial Collaborative Group. Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The magpie trial: a randomised placebo-controlled trial. Lancet, 2002, 359(9321): 1877-1890.
|
| 4. |
Simon J, Gray A, Duley L. Cost-effectiveness of prophylactic magnesium sulphate for 9996 women with pre-eclampsia from 33 countries: economic evaluation of the magpie trial. Br J Obstet Gynaecol, 2006, 113(2): 144-151.
|
| 5. |
Montori VM, Jaeschke R, Schünemann HJ, et al. Users’ guide to detecting misleading claims in clinical research reports. BMJ, 2004, 329(7474): 1093-1096.
|
| 6. |
Luce B, Manning W, Siegel J. Estimating costs in cost-effectiveness analysis. In: Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. Cost-effectiveness in health and medicine. Oxford: Oxford University Press, 1996: 176-213.
|
| 7. |
Friedberg M, Saffran B, Stinson TJ, et al. Evaluation of conflict of interest in economic analyses of new drugs used in oncology. JAMA, 1999, 282(15): 1453-1457.
|
| 8. |
Garber AM, Phelps CE. Economic foundations of cost-effectiveness analysis. J Health Econ, 1997, 16(1): 1-31.
|
| 9. |
Owens DK. Interpretation of cost-effectiveness analyses. J Gen Intern Med, 1998, 13(10): 716-717.
|
| 10. |
Gold M, Siegel JE, Russell LB, et al. Cost-effectiveness in health and medicine. Oxford: Oxford University Press, 1996.
|
| 11. |
O’Brien B, Drummond M, Richardson WS, et al. Economic analysis. In: Guyatt G, Rennie D, eds. Users’ guides to the medical literature. Chicago: AMA Press, 2002, 621-644.
|
1/5
微信公众号